Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
2020
December

December 2020

In Latest NewsPosted December 1, 2020

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

More

Categories

  • Latest News (7)
  • Publication and Data (4)

Recent Posts

  • Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
  • Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
  • Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
  • Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
  • Tallac SITC 2021 Presentation

Archives

  • January 2023
  • November 2022
  • July 2022
  • May 2022
  • October 2021
  • April 2021
  • March 2021
  • December 2020
  • November 2020
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2023 Tallac Therapeutics, Inc. All Rights Reserved.